cefoxitin has been researched along with Salpingitis* in 11 studies
6 trial(s) available for cefoxitin and Salpingitis
Article | Year |
---|---|
A randomized trial of ofloxacin versus cefoxitin and doxycycline in the outpatient treatment of acute salpingitis.
The object of this randomized study was to compare the safety and efficacy of oral ofloxacin, 400 mg twice daily for 10 days, versus intramuscular cefoxitin, 2 gm, plus oral probenecid, 1 gm, followed by oral doxycycline, 100 mg twice daily for 10 days, in the outpatient treatment of uncomplicated acute salpingitis. Thirty-eight women (53%) had Neisseria gonorrhoeae from their pretreatment endocervical or endometrial cultures, and 18 had Chlamydia trachomatis (25%). Thirty-five of 37 women (95%) treated with the ofloxacin regimen were clinically cured, and 34 of 35 (97%) were cured with the cefoxitin-doxycycline regimen (p = 0.52). One clinical failure occurred in each group with N. gonorrhoeae infection, and one failure occurred in the ofloxacin group because of side effects. The bacteriologic response for N. gonorrhoeae in both groups was 100%. The eradication of C. trachomatis was 100% (10/10) for the cefoxitin/doxycycline group and 86% (6/7) for ofloxacin. The side effects were similar in both groups of subjects. In this study both regimens were effective for the outpatient treatment of uncomplicated acute salpingitis. Topics: Acute Disease; Adult; Ambulatory Care; Cefoxitin; Chi-Square Distribution; Chlamydia Infections; Chlamydia trachomatis; Doxycycline; Drug Therapy, Combination; Female; Gonorrhea; Humans; Ofloxacin; Probenecid; Salpingitis | 1991 |
[Acute bacterial salpingitis. The importance of residual inflammation. A comparative study with celioscopic control of 2 antibiotic protocols: sulbactam-ampicillin versus cefoxitin].
The combination of sulbactam-ampicillin was compared to cefoxitin for the treatment of acute salpingitis in 40 women divided into two groups of 20 women each. There were 11 patients in each group who were given doxycycline because of evidence of chlamydial infection. All patients were diagnosed by laparoscopic examination and evaluated by the same procedure 7-12 weeks later: At the second laparoscopy, only 1 of the 20 patients (5%) treated with sulbactam/ampicillin had severe adhesions, while 6 of the 20 patients (40%) treated with cefoxitin had severe adhesions. Tubal patency was without obstruction in 14 patients (70%) given the combination treatment and in 12 patients (60%) given cefoxitin. Side effects were essentially absent in both groups. Topics: Adult; Ampicillin; Bacterial Infections; Cefoxitin; Drug Therapy, Combination; Evaluation Studies as Topic; Female; Humans; Laparoscopy; Prognosis; Salpingitis; Sulbactam | 1990 |
Upper and lower reproductive tract bacteria in 126 women with acute pelvic inflammatory disease. Microbial susceptibility and clinical response to four therapeutic regimens.
To more clearly understand the microbiology of acute salpingitis in our patients and to evaluate the clinical efficacy and safety of recommended and new therapeutic regimens, 126 women who met clinical diagnostic criteria for acute community-acquired pelvic inflammatory disease underwent endocervical and endometrial cultures prior to random intravenous therapy with cefoxitin plus doxycycline, ceftizoxime plus doxycycline or ceftizoxime alone (two regimens). Nine women (7%) had Chlamydia, and 70 (56%) had gonococci in endometrial specimens (P less than .001). Only two women (3.4%) given monotherapy required altered medical therapy, and none required surgery. Parenteral combination therapy was associated more frequently with adverse clinical and laboratory events. Topics: Acute Disease; Adolescent; Adult; Bacteria; Bacterial Infections; Cefoxitin; Ceftizoxime; Doxycycline; Drug Administration Schedule; Drug Therapy, Combination; Endometritis; Female; Humans; Microbial Sensitivity Tests; Prospective Studies; Random Allocation; Salpingitis; Uterine Cervicitis | 1988 |
Measurement of C-reactive protein to compare ceftizoxime versus cefoxitin/doxycycline therapy for septic pelvis: a preliminary report.
C-reactive protein (CRP), a biological marker of inflammation, may be a useful indicator of therapeutic response in patients with septic pelvis. In a study comparing ceftizoxime and cefoxitin/doxycycline in patients with septic pelvis, quantitative CRP levels were closely correlated with the responses and failures of therapy. The results of this study showed the two antibiotic regimens to be equally effective, with 23 of 25 patients in each treatment group achieving a satisfactory response. The fact that ceftizoxime was effective in four of five patients with Chlamydia trachomatis in cervical isolates suggests that intravenous therapy for the acute infection can be accomplished without the addition of an antichlamydial agent. Upon discharge from the hospital, patients can continue therapy with an oral drug that is specifically active against Chlamydia. Topics: C-Reactive Protein; Cefotaxime; Cefoxitin; Ceftizoxime; Chlamydia Infections; Doxycycline; Drug Combinations; Female; Gonorrhea; Humans; Injections, Intravenous; Random Allocation; Salpingitis | 1987 |
Sulbactam/ampicillin versus cefoxitin in the treatment of obstetric and gynaecological infections.
Preliminary results of a randomised trial comparing parenteral sulbactam 1g plus ampicillin 2g every 8 hours and cefoxitin 2g every 8 hours in 75 patients with gynaecological infection are reported. Clinical and bacteriological cure were achieved in 87% and 91% of patients treated with sulbactam/ampicillin compared with 83% and 59% treated with cefoxitin. Both treatments were well tolerated. Topics: Adolescent; Adult; Ampicillin; Bacterial Infections; beta-Lactamase Inhibitors; Cefoxitin; Child; Clinical Trials as Topic; Drug Therapy, Combination; Endometritis; Female; Genital Diseases, Female; Humans; Penicillanic Acid; Peritonitis; Random Allocation; Salpingitis; Sulbactam | 1986 |
Treatment of acute salpingitis with sulbactam/ampicillin. Comparison with cefoxitin.
Sulbactam/ampicillin and cefoxitin were compared in the treatment of 20 patients with acute salpingitis diagnosed during laparoscopy. Results were evaluated during laparoscopic follow-up at 2 months. Sulbactam/ampicillin appeared to be a better treatment, producing better results in tubal patency, adhesions and persistent inflammation than cefoxitin. In addition, the combination of sulbactam/ampicillin with doxycycline appears to provide better results than the combination of cefoxitin with doxycycline in chlamydial salpingitis. It is concluded that sulbactam/ampicillin is an effective treatment for nonchlamydial salpingitis. Topics: Acute Disease; Adult; Ampicillin; Cefoxitin; Chlamydia Infections; Doxycycline; Drug Therapy, Combination; Female; Fertility; Humans; Penicillanic Acid; Prognosis; Salpingitis; Sulbactam; Tissue Adhesions | 1986 |
5 other study(ies) available for cefoxitin and Salpingitis
Article | Year |
---|---|
Fitz-Hugh-Curtis Syndrome Presenting as Acute Abdomen.
Topics: Abdomen, Acute; Anti-Bacterial Agents; Cefoxitin; Doxycycline; Exudates and Transudates; Female; Hepatitis; Humans; Laparoscopy; Metronidazole; Oophoritis; Pelvic Inflammatory Disease; Peritonitis; Salpingitis; Young Adult | 2020 |
Outpatient treatment of pelvic inflammatory disease with cefoxitin and doxycycline.
Sixty-three women with abdominal pain and adnexal tenderness were enrolled in a study of ambulatory treatment of acute pelvic inflammatory disease. Treatment consisted of 2 g of cefoxitin intramuscularly and 1 g of probenecid orally, followed by doxycycline, 100 mg by mouth twice daily for 14 days. Patients were stratified into groups indicating whether pelvic inflammatory disease was probable, possible, or unlikely, based upon endometrial biopsy and clinical criteria. Among 52 women who were evaluated, Chlamydia trachomatis and/or Neisseria gonorrhoeae were initially recovered from 16 (67%) of 24 with probable pelvic inflammatory disease, three (33%) of 11 with possible pelvic inflammatory disease, and three (18%) of 17 in whom pelvic inflammatory disease was considered unlikely. Of the 24 patients with probable pelvic inflammatory disease, 22 (92%) were clinically cured or improved. Of 22 patients initially infected with C trachomatis and/or N gonorrhoeae, 20 were culture-negative for both organisms after therapy. Both microbiologic failures had been reexposed. This study suggests that the combination of cefoxitin and doxycycline is effective for ambulatory treatment of pelvic inflammatory disease. Topics: Adult; Ambulatory Care; Biopsy; Cefoxitin; Chlamydia Infections; Doxycycline; Endometritis; Female; Follow-Up Studies; Gastrointestinal Diseases; Gonorrhea; Humans; Pelvic Inflammatory Disease; Salpingitis | 1988 |
Choice of antibiotics and length of therapy in the treatment of acute salpingitis.
This article reviews the rationale for the therapy of acute salpingitis and the conceptual basis for the length of therapy. The key to therapy of acute salpingitis is the need to accommodate polymicrobial etiology, polymicrobial bacterial superinfection, and the potential presence of penicillinase-producing strains of Neisseria gonorrhoeae into a therapeutic equation that has been determined by the appropriate staging of disease. The anticipated therapeutic response identified for monomicrobial disease due to Neisseria gonorrhoeae constitutes the end titration point for drug administration. Duration of continued therapy beyond this point is governed by the need to complete therapy for Chlamydia trachomatis or to assure resolution of advanced disease. Topics: Acute Disease; Anti-Bacterial Agents; Cefoxitin; Chlamydia Infections; Chlamydia trachomatis; Doxycycline; Drug Therapy, Combination; Female; Gonorrhea; Humans; Metronidazole; Neisseria gonorrhoeae; Penicillinase; Salpingitis; Time Factors | 1985 |
The staging of acute salpingitis and its therapeutic ramifications.
The Gainesville staging of acute salpingitis subdivides the complexity of clinical disease into four major stages. Each stage is predicated upon distinct therapeutic goals and different therapeutic regimens for achieving the principal goal of each stage.. The classical signs of salpingitis are fever, bilateral adnexal tenderness and/or the presence of masses, and signs of an elevated white blood count (WBC) and erythrocite sedimentation rate. These are absent in the majority of women. Acute salpingitis should be suspected in any woman with lower abdominal discomfort and can be verified by needle culdocentesis. Proper staging can be a deciding factor in the patient's cure and future fertility and helps in the selection of antibiotics. The presence or absence of Neisseria gonorrhoeae should be determined first. Some complicating factors during these procedures include: 1) the presence of an IUD when disease within the fallopian tubes tends to be more advanced than can be ascertained from clinical findings, 2) prior inflammatory disease of the fallopian tube, and 3) bilateral tubal ligation. If peritonitis has been inferred by the demonstration of rebound tenderness or by culdocentesis, confirmation can be achieved by ultrasonography or CAT scan of the pelvis. Once the variables have been identified the information can be assessed according to the current classification of acute salpingitis; staging is an attempt to create clinical subjects based upon the fact that each differs in its major therapeutic goal. For acute salpingitis without peritonitis, therapy is with doxycycline. For acute salpingitis with peritonitis, in order to preserve fallopian structure and function, there has to be adequate coverage for principal venereal pathogens, and treatment is a combination of cefoxitin and doxycycline. For acute salpingitis with evidence of tubal occlusion or ruptured tuboovarian complex treatment is with penicillin, clindamycin, and tobramycin. For a case of ruptured tuboovarian complex combinations of antibiotics are used and if these fail surgery is indicated. Topics: Acute Disease; Anti-Bacterial Agents; Bacterial Infections; Cefoxitin; Chlamydia Infections; Doxycycline; Female; Humans; Peritonitis; Salpingitis | 1983 |
Cefoxitin: single-agent treatment of mixed aerobic-anaerobic pelvic infections.
Cefoxitin (mefoxin), a new semisynthetic cephamycin antibiotic, resistant to degradation by beta-lactamase enzymes produced by bacteria. In vitro, cefoxitin is active against virtually all clinically important gram-negative facultative bacteria other than Pseudomonas and Enterobacter spp., gram-positive aerobic bacteria other than the enterococcus, and clinically important anaerobic organisms, including Bacteroides fragilis. This broad antibacterial spectrum suggested that cefoxitin might be an effective single antibiotic agent for the treatment of mixed aerobic-anaerobic infections in obstetric and gynecologic patients. In this investigation, the efficacy and safety of cefoxitin was evaluated in 109 patients--68 with salpingitis, 25 with endomyometritis, 9 with pelvic cellulitis, and 7 with pelvic abscesses. An average of 2.5 bacteria were isolated from each patient. Aerobic bacteria alone was isolated in 38% of patients, anaerobic bacteria alone in 25%, and a combination of aerobic and anaerobic bacteria was isolated in 37% of patients. Overall, 100 of 109 (92%) infections responded to treatment with cefoxitin alone. The major cause of treatment failure was the presence of abscesses requiring surgical drainage. In addition to being an effective single agent for the management of pelvic infections, cefoxitin proved to be safe and well tolerated by patients. Topics: Abscess; Acute Disease; Adolescent; Adult; Aerobiosis; Anaerobiosis; Bacterial Infections; Bacteroides Infections; Cefoxitin; Cellulitis; Cephalosporins; Female; Gonorrhea; Humans; Middle Aged; Pelvis; Salpingitis | 1979 |